Human papillomavirus (HPV) is detected in a vast majority of cervical cancers. For advanced cervical dysplasia (CIN3), co-infection with the human immunodeficiency virus (HIV) can result in more aggressive disease and disease recurrence. Various studies identified that HIV protease inhibitors (HIV-PI) can exert anti-tumor effects outside of its anti-viral activity. In this month's cover image, Qiu and colleagues demonstrate treating cervical cancer tumors with HIV-PIs increase expression of tissue inhibitors of metalloproteinase 3 (TIMP-3, shown in red) on cancer-associated fibroblasts. Read the full article on page 2476.